Article info
PDFBasic and translational research
Concise report
Bcl-2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women
- Correspondence to J-M Anaya, Center for Autoimmune Diseases Research (CREA), School of Medicine, Rosario University; Carrera 24 # 63C-69, Bogotá, Colombia; anayajm{at}gmail.com
Citation
Bcl-2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women
Publication history
- Accepted March 3, 2009
- First published March 11, 2009.
Online issue publication
November 02, 2019
Article Versions
- Previous version (2 November 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved.